MBBS, MD, DM(Medical oncologists) Consultant Medical Oncologist Experience: 8 Years Location: Nellore Timings : 10 AM - 4 PM
Targeted therapy Immunotherapy
Colon & GI Cancer
Kidney & GU Cancer
Breast Cancer Treatment
Thyroid Cancer Palliative treatment Transplant
2012-2015 - Senior Resident at Nims, Hyderabad
2015-2016 - Senior Resident at Ggh, Guntur
2015-2018 - Consultant Medical Oncologist at City Cancer Center, Vijayawada
2018- March 2021 - Consultant Medical Oncologist at Hcg, Vijayawada
April 2021 -till Date - Consultant Medical Oncologist Medicover Cancer Institute, Nellore
Response to Imatinib Mesylate in Childhood Chronic Myeloid Leukemia in Chronic Phase”, South Asian J Cancer 2014 Oct;3(4):203-5.
Impact of Imatinib compliance on the cytogenetic response at six months in pediatric CML CP. Indian Journal of Pediatrics 2016 Feb 3. DOI 10.1007/s12098-015-2007-9.
Impact of treatment protocol on outcome of localized Ewing’s sarcoma. South Asian J Cancer 2016;5:194-5
Trends in management of acute lymphoblastic leukemia: Influence of Insurance based healthcare and treatment compliance on the outcome of adolescents and aduls with acute lymphoblastic leukemia. Indian J Med Paediatr Oncol 2016 Jan-Mar; 37 (1):32-7
Cytogenetic and Molecular response among EUTOS risk groups in children with CML CP on Imatinib treatment. Egypt J Haematol 2017;42:74-7.
Effectiveness of three prognostic scoring systems in predicting the response and outcome in pediatric CML CP on frontline Imatinib. Indian J Med Paediatr Oncol 2017;38:282-6.Imatinib dose hike in suboptimal response and failure in CML CP: Results from a developing nation. journal of Clinical oncology 31,2013_suppl e18003
Cytogenetic and molecular response rates in AYA CML CP patients on imatinib based on the baseline BMI”, Annals of Oncology, Volume 27, Issue suppl_9, December 2016, mdw586.009,
Safety and efficacy of Carboplatin, Capecitabine plus Cetuximab biweekly regimen in the first-line treatment of patients with recurrent/metastatic head and neck cancer (R/MSCCHN): Single center, retrospective study. Annals of Oncology, Volume 29, Issue suppl_9, November 2018, mdy438.029.
Prognostic significance of NLR kinetics in operable triple negative breast cancer. e14201 journal of Clinical oncology 37,2019, no.15_suppl.